摘要
目的：为提高卵巢癌抗独特型抗体的免疫原性，构建表达６Ｂ１１ｓｃＦｖ／ｈＧＭＣＳＦ融合蛋白质，并对其活性进行测定。方法：用ＤＮＡ重组技术，将以前构建的６Ｂ１１ｓｃＦｖＬｉｎｋｅｒｈＧＭＣＳＦ融合基因克隆至ｐＥＴ１６（ａ＋）表达载体，表达可溶蛋白质。用ＥＬＩＳＡ分析技术和细胞增殖试验测定融合蛋白质的抗体和细胞因子活性。结果：融合蛋白质实现可溶表达，能与ＣＯＣ１６６９单抗和小鼠抗人ＧＭＣＳＦ单抗特异结合，并能刺激ＧＭＣＳＦ依赖株增殖。结论：融合蛋白质保留了２种蛋白质的活性。
Objective: To enhance the immunogenecity of anti idiotypic antibody. Methods: Using DNA recombinant techniques, the 6B11scFv/hGM CSF fusion genes were subcloned into bacterial expression vector pET16(a+) to produce soluble proteins. ELISA and cell proliferation assay were used to determine the activities of both proteins of fusion proteins. Results: Fusion proteins were shown to react specifically with primary antibody (Ab1) of 6B11 and inhibit binding of this Ab1 to ovarian serous carcinoma antigen. Fusion proteins could also react with mouse anti human GM CSF monoclonal antibody and stimulate GM CSF dependent cell line TF1 cells to proliferate. Conclusion: The expressed fusion proteins can keep the activity of both proteins and hopefully be used as tumor vaccine against ovarian cancer.
出处
《北京医科大学学报》
CSCD
1998年第5期397-399,403,共4页
Journal of Peking University(Health Sciences)
基金
国家自然科学基金
关键词
卵巢肿瘤
抗独特型抗体
CSF
免疫学
Recombinant fusion proteins/metab
Antibodies
anti idiotypic/metab
Granulocyte macrophage coloing stimulating factor/metab
Ovarian neoplasms/immunol
